An American study, which assessed data from 2016-2019 for newly diagnosed patients with stage IV NSCLC, reported the following testing rates for patients with non-squamous NSCLC: 86% for EGFR, 84% for ALK, 77% for ROS1, 75% for PD-L1, and 62% for BRAF. Here, ROS1 is linked to non-small cell lung carcinoma.